Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:33 AM ET 8-K
Financial Results Intuitive Machines, Inc. LUNR

Intuitive Machines Financial Results

Intuitive Machines reported record third-quarter 2026 financial results, achieving revenue of $269 million and positive free cash flow of $33 million. The company ended the quarter with a record backlog of $1.9 billion, driven by significant contract wins including NASA's $10 billion CLPS 2 IDIQ award and the acquisition of Goonhilly Earth Station.

Term
Q3 2026

“In the third quarter, we delivered record financial performance across the board. These results are an important proof point in our transformation from a company that advanced the state of lunar exploration into a next-generation space prime developing and integrating the technology, infrastructure and services that enable customers to achieve their differentiated missions across space.”

Steve Altemus, CEO

“As we look to turn the corner into 2027, we remain laser focused on IM-3 along with our first Altus-1 lunar satellite, which remains on track for a planned launch in the March/April timeframe. In addition, our emphasis will be to continue to scale execution and accelerate growth. We expect to convert contracted backlog into revenue through repeatable production, operational excellence, and reliable customer delivery.”

Steve Altemus, CEO
7:32 AM ET 10-Q
Financial Results Grace Therapeutics, Inc. GRCE

Grace Therapeutics Q2 2026 Results: Net Loss of $2.13M, Loss Widens

Grace Therapeutics reported a net loss of $17.9 million for the six months ended September 30, 2026, primarily driven by a $13.5 million impairment of intangible assets related to GTx-102 and GTx-101. The company strengthened its liquidity through a $9.2 million private placement in August 2026, providing sufficient cash to fund operations for at least 12 months.

Key figure
Net loss $2.13M
7:32 AM ET 10-Q
Financial Results Lumexa Imaging Holdings, Inc. LMRI

Lumexa Imaging Holdings Q3 2026 Results: Turns Profitable, Net Income $7.18M

Lumexa Imaging Holdings reported a net income of $7.2 million for the third quarter of 2026, a significant recovery from a $3.5 million loss in the prior year period. Total revenues grew to $272.0 million, driven by increases in net patient service and management fee revenue, while the company maintained a strong cash position of $90.0 million.

Key figure
Net income $7.18M
7:31 AM ET 10-Q
Financial Results Btcs Inc. BTCS

Btcs Q3 2026 Results: Net Income $54.5M, Down 16.9% YoY

For the nine months ended September 30, 2026, BTCS Inc. reported total revenues of $8.7 million and a net loss of $49.5 million, primarily driven by $30.6 million in realized losses on digital asset transactions and $11.2 million in impairment losses. This represents a significant downturn from the $52.2 million net income reported in the prior year period, despite a substantial increase in DeFi-related revenue.

Key figure
Net income $54.5M · -16.9% YoY
7:31 AM ET 10-Q
Financial Results Taysha Gene Therapies, Inc. TSHA

Taysha Gene Therapies Q3 2026 Results: Net Loss of $39.1M, Loss Widens

Taysha Gene Therapies reported a net loss of $128.2 million for the nine months ended September 30, 2026, compared to $81.1 million in the prior year, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through an underwritten public offering that raised approximately $215.7 million, ending the period with $422.8 million in cash and cash equivalents.

Key figure
Net loss $39.1M
7:31 AM ET 10-Q
Financial Results Falcon's Beyond Global, Inc. FBYD

Falcon's Beyond Global Q3 2026 Results: Net Loss of $3.86M, Loss Narrows

Falcon's Beyond Global, Inc. reported that as of November 12, 2026, it had 49,226,743 Class A and 72,169,750 Class B shares outstanding. The company disclosed substantial doubt about its ability to continue as a going concern due to current liquidity resources and noted material adverse impacts from impairments of intangible assets and equity method investments.

Key figure
Net loss $3.86M
7:31 AM ET 10-Q
Financial Results Capstone Holding Corp. CAPS

Capstone Holding Q3 2026 Results: Net Loss of $632K, Loss Narrows

Capstone Holding Corp. reported net sales of $54.1 million for the nine months ended September 30, 2026, a significant increase from $34.4 million in the prior year. Despite higher sales, the company incurred a net loss of $3.9 million for the period, though this was an improvement over the $4.4 million net loss reported in 2025.

Key figure
Net loss $632K
7:31 AM ET 10-Q
Financial Results Sagimet Biosciences Inc. SGMT

Sagimet Biosciences Q3 2026 Results: Net Loss of $19.1M, Loss Widens

Sagimet Biosciences Inc. reported a significant increase in total assets to $282.1 million as of September 30, 2026, up from $116.5 million at the end of 2025, primarily driven by growth in cash and marketable securities. The company is advancing its lead drug candidate, denifanstat, through clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Current liabilities also increased to $38.0 million, including a $27.5 million liability for proceeds received for equity not yet issued.

Key figure
Net loss $19.1M
7:31 AM ET 8-K
Financial Results Yesway, Inc. YSWY

Yesway Financial Results

Yesway, Inc. reported third quarter 2026 financial results, featuring a net income increase to $24.8 million and an 8.6% rise in Adjusted EBITDA to $59.6 million. The company achieved same-store inside merchandise sales growth of 1.9% and expanded its footprint by opening two new stores, including its first location in Arizona.

“We delivered another exceptional quarter, building on our strong performance in the first half of 2026. We continued to grow inside merchandise sales and fuel gallons, expand our market share, and deliver strong profitability against a challenging consumer environment.”

Thomas N. Trkla, Chairman, President and Chief Executive Officer

“We are proud of what our team has accomplished and excited for what is ahead for Yesway as we continue to advance our three growth priorities – new store development, initiatives that strengthen our existing operations, and selective acquisitions – and drive long-term value for all our stakeholders.”

Thomas N. Trkla, Chairman, President and Chief Executive Officer
7:26 AM ET 10-Q
Financial Results Howard Hughes Corp HHC

Howard Hughes Q3 2026 Results: Net Loss of $51.1M

For the nine months ended September 30, 2026, Howard Hughes Corp reported total revenues of $1.52 billion, a significant increase from $850.4 million in 2025, primarily driven by a surge in condominium rights and unit sales. Net income attributable to the company rose to $144.4 million for the nine-month period, despite a net loss of $49.9 million in the third quarter due to a $105.4 million loss on the sale of Municipal Utility District receivables.

Key figure
Net loss $51.1M
7:24 AM ET 10-Q
Financial Results Kioni Holdings Ltd KNIH

Kioni Holdings Q3 2026 Results: Net Income $20.3K, Up 94.1% YoY

Kioni Holdings reported a net loss of $116,663 for the nine months ended September 30, 2026, compared to a net profit of $33,674 in the prior year period, primarily due to a significant increase in general and administrative expenses. Despite the year-to-date loss, the company achieved a net profit of $20,343 for the third quarter of 2026 on revenues of $67,722.

Key figure
Net income $20.3K · +94.1% YoY
7:24 AM ET 8-K
Financial Results Legence Corp. LGN

Legence Financial Results

Legence Corp. reported record Q3 2026 revenue of $1.31 billion, an 85% increase year-over-year, driven by strong customer demand and the Bowers acquisition. The company also announced that its Board of Directors authorized a new $150 million stock repurchase program and raised its full-year 2026 financial guidance.

Term
Q3 2026

“Strong customer demand drove record third-quarter revenue, Adjusted EBITDA, and backlog and awarded contracts for Legence. Our team continues to deliver exceptional project execution, which along with an increasing mix of fabrication work, contributed to the delivery of the highest Adjusted EBITDA margin in company history.”

Jeff Sprau, Chief Executive Officer of Legence
7:23 AM ET 6-K
Financial Results Orix Corp IX

Orix H2 2026 Results: Net Income $856B, Up 215.8% YoY

ORIX CORP reported a significant decrease in provision for credit losses to ¥1,830 million for the six months ended September 30, 2026, compared to ¥9,781 million in the prior year period. The company utilized fair value options for various assets, including foreign government bonds and loans held for sale, with the latter experiencing a fair value loss of ¥3,152 million in the current period.

Key figure
Net income $856B · +215.8% YoY
7:21 AM ET 10-Q
Financial Results CoreWeave, Inc. CRWV

CoreWeave Q3 2026 Results: Net Loss of $709M, Loss Widens

CoreWeave reported significant growth for the nine months ended September 30, 2026, with revenue reaching $8.31 billion compared to $3.56 billion in the prior year period. However, the company experienced a substantial increase in operating expenses, particularly in technology and infrastructure, and reported an accumulated deficit of $4.72 billion as of the end of the third quarter.

Key figure
Net loss $709M
7:20 AM ET 8-K
Financial Results Twist Bioscience Corp TWST

Twist Bioscience Financial Results

Twist Bioscience reported record fiscal 2026 revenue of $459.4 million, a 22% increase year-over-year, driven by strong growth in DNA Synthesis and NGS Applications. The company achieved positive adjusted EBITDA in the fourth quarter and improved its annual gross margin to 52.4%. Management issued fiscal 2027 revenue guidance of $550 million to $560 million, representing approximately 21% growth at the midpoint.

Term
FY2026

“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet.”

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience

“We enter fiscal 2027 with a stronger business and the capital to invest in our next phase of growth. AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules. Both play directly to our strength of customization at scale.”

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience
7:19 AM ET 10-Q
Financial Results Asiafin Holdings Corp. ASFH

Asiafin Holdings Q3 2026 Results: Net Loss of $47.1K

AsiaFIN Holdings Corp. reported revenue of $3.96 million for the nine months ended September 30, 2026, a significant increase from $3.20 million in the prior year period. The company achieved a net income of $198,145 for the first nine months of 2026, successfully rebounding from a net loss of $326,764 during the same period in 2025.

Key figure
Net loss $47.1K
7:18 AM ET 8-K
Financial Results Flyexclusive Inc. FLYX

Flyexclusive Financial Results

flyExclusive, Inc. reported its unaudited financial results for the third quarter ended September 30, 2026. The company filed both a formal press release and a corporate earnings presentation to review its performance and structurally improved business model.

Term
Q3 2026
7:17 AM ET 8-K
Financial Results Century Therapeutics, Inc. IPSC

Century Therapeutics Financial Results

Century Therapeutics reported third quarter 2026 financial results and provided updates on its iPSC-derived cell therapy pipeline. The company remains on track for an IND submission for CNTY-813 in Q4 2026 and expects its CD19-targeted CAR-iT cell therapy, CNTY-308, to enter the clinic by the end of 2026.

“We remain focused on disciplined execution as we rapidly advance our two potentially transformational programs, including CNTY-813, which has the potential to be a functional cure for type 1 diabetes, toward the clinic over the coming months.”

Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics

“With general alignment reached with the FDA for both programs, we remain on track this year for clinical entry of CNTY-308 and IND submission of CNTY-813, positioning us for an important transition to clinical execution in 2027.”

Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics
7:16 AM ET 10-Q
Financial Results Pelthos Therapeutics Inc. PTHS

Pelthos Therapeutics Q3 2026 Results: Net Loss of $7.89M, Loss Narrows

Pelthos Therapeutics reported total revenue of $41.9 million for the nine months ended September 30, 2026, a significant increase from $7.4 million in the prior year. Despite the revenue growth, the company recorded a net loss of $56.4 million due to high selling, general, and administrative expenses and a $9.3 million loss from the change in fair value of convertible debt.

Key figure
Net loss $7.89M
7:16 AM ET 8-K
Financial Results Generate Biomedicines, Inc. GENB

Generate Biomedicines Financial Results

Generate Biomedicines reported third quarter 2026 financial results, highlighting a cash position of $404.2 million and progress in its Phase 3 asthma studies for GB-0895. The company also noted a significant collaboration with Zealand Pharma in obesity and metabolic diseases with total potential milestones of nearly $1.2 billion.

“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence. We are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing.”

Mike Nally, chief executive officer of Generate Biomedicines
7:16 AM ET 10-Q
Financial Results TScan Therapeutics, Inc. TCRX

TScan Therapeutics Q3 2026 Results: Net Loss of $33.1M, Loss Narrows

TScan Therapeutics reports significant ongoing losses and has identified conditions raising substantial doubt about its ability to continue as a going concern. The company is currently non-compliant with Nasdaq's continued listing requirements and requires substantial additional funding to advance its TCR-T therapy product candidates through clinical development.

Key figure
Net loss $33.1M
7:16 AM ET 8-K
Financial Results DPC Holdings PLC DPC

DPC Holdings Financial Results

DPC Holdings reported record Q3 2026 financial results with revenue of $308.1 million, up 39% year-over-year, and a return to GAAP profitability with net income of $31.8 million. The company also announced the acquisition of a 50% stake in Montana Precision Products and a new 10-year strategic customer partnership involving a $200 million capacity investment.

Term
Q3 2026
7:15 AM ET 10-Q
Financial Results Flyexclusive Inc. FLYX

Flyexclusive Q3 2026 Results: Net Loss of $7.65M, Loss Widens

For the nine months ended September 30, 2026, flyExclusive reported revenue of $318.5 million, an increase from $271.6 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $37.8 million, though this was an improvement over the $60.2 million net loss reported for the same period in 2025.

Key figure
Net loss $7.65M
7:15 AM ET 8-K
Financial Results Adi Global Distribution Inc. ADIG

Adi Global Distribution Financial Results

ADI Global Distribution reported Q3 2026 net revenue of $1.31 billion, an 8.6% increase year-over-year, though it recorded a net loss of $655 million due to a significant $659 million non-cash goodwill impairment charge. The impairment was triggered by continued weakness in the residential market and lower projected earnings, leading the company to update its full-year 2026 financial guidance.

7:15 AM ET 8-K
Financial Results Solv Energy, Inc. MWH

Solv Energy Financial Results

SOLV Energy reported record third quarter 2026 financial results with revenue increasing 65% year-over-year to $1.24 billion. The company highlighted a total backlog of approximately $9.2 billion and raised its full-year 2026 financial guidance following the acquisition of ASB Energy Services.

Term
Q3 2026

“SOLV delivered another quarter of strong results, driven by continued execution across the business, our focus on safety, and the dedication of our employees. With a growing backlog, momentum across our operations, and continued demand across our markets, we are raising our full-year guidance and remain focused on disciplined execution, responsible growth, and expanding the value we provide to our customers.”

George Hershman, Chief Executive Officer of SOLV Energy
7:15 AM ET 10-Q
Financial Results Absci Corp ABSI

Absci Q3 2026 Results: Net Loss of $33.3M, Loss Widens

Absci Corp reported a net loss for the third quarter of 2026 and continues to incur significant losses as it funds its Integrated Drug Creation platform and internal drug programs. As of October 30, 2026, the company had 172,745,810 shares of common stock outstanding and indicated a need for additional capital to fund future operations and clinical development.

Key figure
Net loss $33.3M
7:11 AM ET 8-K
Financial Results Absci Corp ABSI

Absci Financial Results

Absci Corp reported third quarter 2026 financial results and provided updates on its generative AI-designed therapeutic pipeline. The company is on track to release interim proof-of-concept data for its ABS-201 program in pattern hair loss in December 2026 and plans to initiate a Phase 2 trial for endometriosis in mid-2027.

“As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for the opportunity to potentially demonstrate our program's ability to stimulate hair regrowth in a convenient and durable way.”

Sean McClain, Founder and CEO

“As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs. In line with that strategy, we are thrilled to be welcoming Gerry Muhle to Absci as our Chief Commercial Officer, whose experience we believe will position ABS-201 and our expanding program pipeline for success.”

Sean McClain, Founder and CEO
7:11 AM ET 10-Q
Financial Results Kardigan, Inc. KARD

Kardigan Q3 2026 Results: Net Loss of $58.6M, Loss Narrows

Kardigan, Inc. is a clinical-stage biopharmaceutical company focusing on cardiovascular diseases with lead candidates Danicamtiv, Ataciguat, and Tonlamarsen. As of November 2026, the company is an emerging growth company with 93,597,398 shares of common stock outstanding and continues to anticipate significant financial losses as it funds its clinical trials and Prolaio platform development.

Key figure
Net loss $58.6M
7:11 AM ET 8-K
Financial Results Data I DAIO

Data I Financial Results

Data I/O Corporation reported Q3 2026 revenues of $4.9 million and highlighted the October completion of its $23 million acquisition of V-TEK, Inc. and A&J Programming. The company secured $13.25 million in direct investment and a $7.5 million credit line to fund the transformational deal, which is expected to double revenues and diversify the business into AI, photonics, and robotics markets.

Term
Q3 2026

“The most important measure of our recent performance and our prospects for the future is the completion of the transformational acquisition of V-TEK.”

William Wentworth, President and CEO of Data I/O Corporation

“The NEW Data I/O has become a reality. With the V-TEK acquisition, our expanded products and services now address multibillion-dollar markets. The NEW Data I/O serves industries such as data centers, AI, photonics, industrial automation, robotics, medical, military, aerospace and defense, significantly reducing our reliance on automotive.”

William Wentworth, President and CEO of Data I/O Corporation
7:10 AM ET 8-K
Financial Results Pelthos Therapeutics Inc. PTHS

Pelthos Therapeutics Financial Results

Pelthos Therapeutics reported Q3 2026 financial results, highlighted by Zelsuvmi net product revenue of $15.2 million, a 114% increase year-over-year. The company also highlighted its pending transformative merger with Castle Creek Biosciences, which was announced in October 2026 to create a diversified biotechnology company focused on skin diseases.

“Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million. Thousands of patients have already benefited from Zelsuvmi and we remain focused on driving Zelsuvmi growth and building on our success with the planned launches of Xepi® targeted in the first quarter of 2027 and Xeglyze® targeted in the third quarter of 2027.”

Scott Plesha, CEO of Pelthos

“In October, after the close of the third quarter, we took an important step in our pursuit of long-term value by announcing our agreement to combine with Castle Creek, a transaction that we believe will create a stronger, more diversified biotechnology company.”

Scott Plesha, CEO of Pelthos

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.